Comparative Pharmacology
Head-to-head clinical analysis: FYLNETRA versus NIVESTYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYLNETRA versus NIVESTYM.
FYLNETRA vs NIVESTYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYLNETRA (filgrastim-ayow) is a granulocyte colony-stimulating factor (G-CSF) analog that binds to the G-CSF receptor on neutrophils and their precursors, stimulating proliferation, differentiation, and functional activation of neutrophils.
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
3.6 mg/kg subcutaneously once daily for up to 14 days. Dose based on absolute neutrophil count.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days until absolute neutrophil count reaches 10,000/mm³ after nadir; or 5 mcg/kg subcutaneously once daily for 5 days for mobilization of peripheral blood progenitor cells.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (range 2–5 hours); supports daily dosing in most patients for myelosuppressive chemotherapy.
Terminal elimination half-life approximately 3.5 hours (subcutaneous) in healthy volunteers; in patients undergoing chemotherapy, half-life may be prolonged (up to 4-6 hours) due to neutrophil-mediated clearance.
Renal (primarily, as unchanged drug and metabolites, minor biliary/fecal)
Primarily renal (via degradation to peptides and amino acids); <1% excreted unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor